GSK (GSK) shares rose in early trading on Tuesday after the US Food and Drug Administration published documents related to a potential approval of the company's blood cancer drug, Bloomberg reported.
The FDA's Oncologic Drugs Advisory Committee is scheduled to meet on Thursday to discuss GSK's Blenrep, Bloomberg reported, adding that a decision on approval of the drug is expected by July 23.
Blenrep has been approved in the UK in combination with other oncology drugs to treat certain patients with multiple myeloma, an incurable blood cancer, Bloomberg reported.
GSK shares were 0.7% higher in recent trading.
(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)
Price: 38.54, Change: +0.24, Percent Change: +0.63
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。